Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and autoimmune disorders, such as different types of arthritis and cytokine release syndrome. It was later approved by Health Canada on 30 April 2010. After being investigated to treat severely ill patients with COVID-19, tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving systemic corticosteroids and supplemental oxygen or mechanical ventilation. Subsequently, it was granted approval by Health Canada and the FDA in October and December 2022, respectively. Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023.
Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
Tocilizumab is also used to treat coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
University Hospital Bern, Inselspital, Bern, Switzerland
Site KR82003, Daegu, Korea, Republic of
Site KR82007, Daegu, Korea, Republic of
Site KR82002, Incheon, Korea, Republic of
Massachusetts General Hospital, Boston, Massachusetts, United States
Froedtert Hospital, Milwaukee, Wisconsin, United States
Fort Wayne Medical Institute, Fort Wayne, Indiana, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
University of Alabama Birmingham, Birmingham, Alabama, United States
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
University of California; Moores Cancer Center, La Jolla, California, United States
University of Pittsburgh - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
University of Miami Miller School of Medicine, Miami, Florida, United States
University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Princess Margaret Cancer Center, Toronto, Ontario, Canada
Clinica Universitaria de Navarra, Pamplona, Navarra, Spain
Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain
UZ Gent, Gent, Belgium
Novant Health Cancer Institute, Charlotte, North Carolina, United States
Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT, København Ø, Denmark
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.